Gregory Ginger 4

What Happened

• Gregory Ginger, Executive Vice President, Human Resources at Biogen, received an award of 8,025 restricted stock units (RSUs) reported on Feb 13, 2026. The grant is reported as an acquisition at $0.00 (transaction code A), meaning no cash was paid for the award.
• This is a compensation grant (derivative award), not an open-market purchase or sale; the RSUs convert to actual shares only as they vest.

Key Details

• Transaction date: February 13, 2026; Form 4 filed February 17, 2026.
• Securities granted: 8,025 RSUs; reported price: $0.00.
• Vesting: RSUs vest in three equal yearly installments beginning on the first anniversary of the grant (first vesting Feb 13, 2027), i.e., likely vesting dates Feb 13 of 2027, 2028 and 2029.
• Shares owned after the transaction: not specified in the provided filing excerpt.
• Filing note: reported on a Form 4 filed 4 days after the grant date; the filing itself does not state any 10b5‑1 plan or tax‑withholding details in the excerpt provided.

Context

• RSU grants are standard executive compensation and represent future potential ownership as units convert to shares upon vesting; they are not immediate market purchases or sales.
• For retail investors, such awards signal routine compensation alignment with company performance/retention policies rather than an immediate insider market view.